NASDAQ:LIXT Lixte Biotechnology (LIXT) Stock Price, News & Analysis $2.63 +0.61 (+30.15%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$2.38 -0.25 (-9.66%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lixte Biotechnology Stock (NASDAQ:LIXT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lixte Biotechnology alerts:Sign Up Key Stats Today's Range$2.44▼$4.2550-Day Range$0.71▼$2.6352-Week Range$0.64▼$4.25Volume64.13 million shsAverage Volume650,780 shsMarket Capitalization$7.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. Read More Lixte Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreLIXT MarketRank™: Lixte Biotechnology scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lixte Biotechnology. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lixte Biotechnology is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lixte Biotechnology is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Lixte Biotechnology's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.22% of the float of Lixte Biotechnology has been sold short.Short Interest Ratio / Days to CoverLixte Biotechnology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lixte Biotechnology has recently decreased by 55.88%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLixte Biotechnology does not currently pay a dividend.Dividend GrowthLixte Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.22% of the float of Lixte Biotechnology has been sold short.Short Interest Ratio / Days to CoverLixte Biotechnology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lixte Biotechnology has recently decreased by 55.88%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.06 News SentimentLixte Biotechnology has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Lixte Biotechnology this week, compared to 0 articles on an average week.Search Interest2 people have searched for LIXT on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders14.80% of the stock of Lixte Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.10% of the stock of Lixte Biotechnology is held by institutions.Read more about Lixte Biotechnology's insider trading history. Receive LIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address LIXT Stock News HeadlinesWall Street Today: S&P 500, Nasdaq rise as job data exceeds market expectations amid Trump tariff concernsJuly 4 at 6:09 AM | msn.comLixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market | MorningstarJuly 4 at 2:08 AM | morningstar.comMElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)Lixte Biotechnology (NASDAQ:LIXT) Stock, Insider Trading ActivityJuly 3, 2025 | benzinga.comLixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market | MorningstarJuly 2, 2025 | morningstar.comMLixte Biotechnology secures $5 million in private placementJuly 2, 2025 | investing.comLixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the MarketJuly 2, 2025 | globenewswire.comLixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the MarketJuly 1, 2025 | globenewswire.comSee More Headlines LIXT Stock Analysis - Frequently Asked Questions How have LIXT shares performed this year? Lixte Biotechnology's stock was trading at $2.03 on January 1st, 2025. Since then, LIXT shares have increased by 29.5% and is now trading at $2.6290. How were Lixte Biotechnology's earnings last quarter? Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.29) earnings per share (EPS) for the quarter. When did Lixte Biotechnology's stock split? Lixte Biotechnology's stock reverse split before market open on Monday, June 5th 2023.The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lixte Biotechnology IPO? Lixte Biotechnology (LIXT) raised $7 million in an IPO on Wednesday, November 25th 2020. The company issued 1,500,000 shares at a price of $4.75 per share. WestPark Capital and WallachBeth Capital acted as the underwriters for the IPO. How do I buy shares of Lixte Biotechnology? Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lixte Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT). Company Calendar Last Earnings5/12/2025Today7/06/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LIXT CIK1335105 Webwww.lixte.com Phone(631) 830-7092Fax631-982-5050Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.59 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-189.35% Debt Debt-to-Equity RatioN/A Current Ratio4.26 Quick Ratio4.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.19) per share Price / Book-2.21Miscellaneous Outstanding Shares2,684,000Free Float2,287,000Market Cap$7.06 million OptionableNot Optionable Beta0.31 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:LIXT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.